ClinicalTrials.gg
RecruitingNCT06005532Updated Nov 29, 2023

Study Evaluation of the Efficacy, Safety and Immunogenicity of Adalimumab in Comparison With Humira®

A Phase 3 interventional study of Adalimumab and Humira in Plaque Psoriasis, sponsored by Mabscale, LLC. Recruiting at 9 sites in Russian Federation. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-11-29.

Sponsored by Mabscale, LLC · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Mar 2025, 1 year 8 months ago, but the record still lists the study as recruiting.
  • Started Oct 2023; still recruiting 3 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
494
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 48 studies testing adalimumab in Psoriasis — 6 open to participants now, 6 under way, 1 of them phase 3. Adalimumab · Psoriasis.

Planned enrollment
5th of 48
494 · median 148
Started
2023
with 2 others
Phase 3
26 of 48
1 open now
Registered
44th of 48
by date

Among the 48 studies testing adalimumab in Psoriasis, this one is the 5th largest by planned enrollment, is one of 3 that started in 2023, is one of 26 in phase 3, and was the 44th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

6 of the 48 studies testing adalimumab in Psoriasis are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies testing adalimumab in Psoriasis, or all of them as a file.
02

Study summary

MABPS-3/2020 is a double-blind randomized multicenter clinical trial comparing efficacy, immunogenicity and safety profiles of Adalimumab (manufactured by Mabscale, LLC) compared to Humira®.

The purpose of the study is to demonstrate efficacy, immunogenicity and safety of Adalimumab (manufactured by Mabscale, LLC) to Humira ® in adult patients with chronic plaque psoriasis of moderate and severe degree.

Read the detailed description

Adalimumab is a recombinant humanized monoclonal antibody currently being developed by Mabscale LLC, as a proposed biosimilar to Humira®, which is approved as treatment in patients with chronic plaque psoriasis.

This randomized equivalence study is designed to meet the regulatory requirement for approval of a biosimilar product.

03

Conditions studied

  • Plaque Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written .
  2. Male and female patients aged 18-65 years, body weight ≥ 50 kg and ≤ 120 kg.
  3. Established clinical diagnosis plaque psoriasis, lasting at least 6 months before the screening.
  4. Plaque psoriasis of moderate or severe severity of stable course with:

    • PASI ≥ 12 points;
    • BSA ≥ 10 %;
    • sPGA ≥ 3 points.
  5. Patients who have been shown to undergo systemic therapy and/or patients who have had insufficient therapeutic efficacy of at least 1 previous standard systemic therapy for psoriasis, including phototherapy, therapy with cytostatic and drugs, or who have had intolerance to standard systemic therapy.

Exclusion criteria

Exclusion Criteria:

  1. Data on intolerance or to any components of the drugs, or to any other human proteins, immunoglobulin preparations.
  2. A history of severe hypersensitivity reactions of any etiology.
  3. Other (other than plaque) forms of psoriasis.
  4. Drug-induced psoriasis.
  5. Data on the use of the Adalimumab or any preparations of monoclonal antibodies inhibiting TNF-α at any time during life.
  6. The presence of Adalimumab antibodies.
  7. Extensive surgical intervention performed less than 30 days before the screening period, or planned extensive surgical intervention during the study period.
  8. Active or latent tuberculosis
  9. Lymphoproliferative diseases, lymphoma, leukemia, myeloproliferative diseases or a history of multiple myeloma.
  10. Any other malignant neoplasms currently or in anamnesis within the last 5 years, with the exception of completely removed and/or cured.
  11. Confirmed coronavirus infection caused by COVID-19 within 8 weeks prior to the screening period.
  12. Anamnestic data on the presence of syphilis, viral , viral , .
  13. Vaccination with live or attenuated vaccines within 8 weeks before the screening period.
  14. Hepatic and/or renal insufficiency.
  15. Pregnancy or lactation.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
494 participants (estimated)

Study arms

  • Experimental
    Adalimumab (manufactured by Mabscale, LLC)

    In the main period, patients will begin Visit 1 receiving Adalimumab therapy at an initial dose (80 /0, 16 ml) on Visit 1, from Visit 2 Adalimumab therapy at a maintenance dose (40 /0, 8 ml) for up to Visit 9 of therapy. Each visit is conducted every two weeks ± 2 days. In additional period (from Visit 11 until Visit 28), eligible patients will continue to receive treatment after additional randomization (Adalimumab or Humira® (40 /0, 8 ml)) every 2 weeks until the end of a trial.

    Drug: Adalimumab

  • Active comparator
    Humira®

    In the main period, patients will begin Visit 1 receiving Humira® therapy at an initial dose (80 /0, 8 ml) on Visit 1, from Visit 2 Humira® therapy at a maintenance dose (40 /0, 4 ml) for up to Visit 9 of therapy. Each visit is conducted every two weeks ± 2 days. In additional period (from Visit 11 until Visit 28), eligible patients will continue to receive treatment after additional randomization (Adalimumab or Humira® (40 /0, 4 ml)) every 2 weeks until the end of a trial.

    Drug: Humira

Interventions

  • Adalimumab injection 40 mg / 0.8 ml

  • DrugHumira

    Adalimumab injection 40 mg / 0.4 ml

06

What researchers measure

Primary outcomes

  1. The proportion of patients who achieved a response according to the PASI criterion of 75 (a decrease in the severity and prevalence of psoriasis by ≥75% from the baseline level assessed by the PASI index)

    Time frame: after 16 weeks of therapy (assessment at Visit 10)

  2. Proportion of patients with positive antibody titer to Adalimumab

    Time frame: 51 weeks of therapy

  3. Percentage of patients who have neutralizing antibodies to Adalimumab

    Time frame: 51 weeks of therapy

07

Study locations

2 of 9 sites recruiting
  • Regional dermatovenerologic dispensary
    Barnaul, Russian Federation
    Recruiting
    • Kovaleva · Contact
  • Chelyabinsk Regional Clinical Dermatovenerologic Dispensary
    Chelyabinsk, Russian Federation
    Recruiting
    • Ziganshin · Contact
  • Interregional Clinical Diagnostic Center
    Kazan', Russian Federation
    Not yet recruiting
    • Isaeva · Contact
  • City clinical hospital n.a.Botkin
    Moscow, Russian Federation
    Not yet recruiting
    • Sotnikova · Contact
  • Rheumatology research Instititue n.a.Nasonova
    Moscow, Russian Federation
    Not yet recruiting
    • Korsakova · Contact
  • State Scientific Center of Dermatovenerology and Cosmetology
    Nizhny Novgorod, Russian Federation
    Not yet recruiting
    • Gorodnichev · Contact
  • Reafan
    Novosibirsk, Russian Federation
    Not yet recruiting
    • Filippova · Contact
  • New Clinic
    Pyatigorsk, Russian Federation
    Not yet recruiting
    • Chistyakova · Contact
  • Dermatovenerologic dispensary N10
    Saint Petersburg, Russian Federation
    Not yet recruiting
    • Sukharev · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Mar 2025, 17 months after the start.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's planned 17 months is above that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 5, 2023
First posted
Aug 22, 2023
StartActual
Oct 2, 2023
Primary completionEst.
Mar 2025
CompletionEst.
Dec 2025
Last update
Nov 29, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06005532
Lead sponsor
Mabscale, LLC
Responsible party
Sponsor
First posted
Aug 22, 2023
Start date
Oct 2, 2023
Primary completion
Mar 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Nov 29, 2023

Study contacts

Yulia BASKAEVA
Contact
baskaeva.y@benerix.ru
+74997149289

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion